NanoViricides' NV-387: A Broad-Spectrum Antiviral Candidate for Future COVID Strains

NanoViricides' broad-spectrum antiviral NV-387 may address emerging COVID variants like the "Stratus" strain. It has completed Phase 1 trials with no adverse events and demonstrated greater effectiveness than remdesivir in preclinical studies. NV-387 targets a viral mechanism unlikely to change, making it effective against future COVID variants and other viruses like influenza, RSV, and Mpox. The drug is orally available and manufactured in the USA.